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were published in peer-reviewed journals. Search was conducted using generic
names of the drugs and the phrase “cost effectiveness” in abstract of the published
study. RESULTS: During 2003-2008, the number of published studies on “cost ef-
fectiveness” have increased by more than 30%. There is a large variability in CERs
for same drugs for different indications, in some cases also varying by biomarkers.
Primary care drugs had lower and less variable CERs than specialty drugs. Varia-
tions also exist in methodology used by different groups in modeling cost effec-
tiveness, especially for time horizon and comparator. Majority of primary care
drugs were modeled for a time horizon of 35-40 years or lifetime to demonstrate
cost effectiveness. CONCLUSIONS: This analysis shows the range, variability and
methods used for calculation of ICER values for these high budget impact drugs and
provides lessons for executives and policy makers.
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THE COST-EFFECTIVENESS OF ROFLUMILAST IN THE MANAGEMENT OF
SEVERE COPD IN THE UK SETTING
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OBJECTIVES: Despite availability of current treatments, patients with chronic ob-
structive pulmonary disease (COPD), associated with chronic bronchitis, often ex-
perience frequent (life-threatening and costly) exacerbations in UK clinical prac-
tice. The aim of this analysis was to estimate the long-term costs and health
outcomes associated with the use of roflumilast in the maintenance treatment of
severe COPD in the UK setting. METHODS: A Markov model was constructed to
simulate the decline of patients through stages of COPD (as defined by the GOLD
guidelines) and death. Transition probabilities were derived from published epide-
miological sources. Community- andhospital-treated exacerbationsweremodeled
as events within each health-state. Analysis was conducted for roflumilast in dif-
ferent positions within the care pathway: replacing LABA/ICS as an add-on to LA-
MA; replacing LAMA as an add-on to LABA/ICS, and; add-on to triple therapy
(LAMALABA/ICS) vs. placebo. Relative rate ratios of exacerbations for therapeutic
regimens were derived from an independently-conducted mixed treatment com-
parison. Direct costs, health state utilities and exacerbation disutilities were
sourced fromUK costs and the published literature. Analyseswere conducted from
the UKNHS perspective, based on a 30-year time horizon, with costs and outcomes
discounted at 3% p.a. One-way and probabilistic sensitivity analyses were
conducted. RESULTS: At monthly cost of £38.23, replacement of LABA/ICS with
roflumilast was shown to be a dominant strategy, projected to improve quality-
adjusted life expectancy by 0.104 QALYs, and reduce total costs by £400. Replace-
ment of LAMAwith roflumilast yielded an ICER of £6,854/QALY; adding roflumilast
onto triple therapy yielded an ICER of £24,603/QALY. Results were sensitive to the
cost of hospital-treated exacerbations, relative rates of exacerbation and drug
costs. CONCLUSIONS: Roflumilastmay represent a cost-effective treatment option
in the UK, when used as either an add-on to, or replacement for existing agents, in
the management of severe COPD patients.
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COST-UTILITY OF VARENICLINE VERSUS INTERVENTIONS AVAILABLE FOR
QUITTING SMOKING IN PANAMA USING THE BENESCO MODEL
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OBJECTIVES: In Panama, between 13.5-16.5% of all deaths are associated to tobacco
consumption. The Ministry of Health (MoH) determined that tobacco use is asso-
ciated to seven of the leading causes of death in the country. The aim of this study
was to estimate the incremental cost–utility ratios for varenicline compared to
bupropion, nicotine replacement therapy (NRT) and unaided cessation for quitting
smoking using a time-horizon of 20 years from an institutional perspective.
METHODS: The Benefits of Smoking Cessation on Outcomes(BENESCO) simulation
model was used for an adult cohort of subjects (n2,249,676). BENESCO model
contains projected outcomes for cardiovascular diseases, chronic obstructive pul-
monary disease, lung cancer and stroke. The smoking cessation therapies evalu-
ated were: varenicline (0.5–2 mg/day) versus bupropion (300 mg/day), NRT (5-10
mg/day) and unaided cessation. Effectiveness and utility measures were collected
frompublished literature. Unit costs and resource use used datawas gathered from
the Panama’s MoH(2009). Costs (expressed in 2009US$) and health outcomes were
discounted at 3%. Probabilistic sensitivity analyses (PSA) were conducted.
RESULTS: Smoking cessation efficacy rates were: 22.5%; 15.7%; NRT 13.7% and 5.9%
for varenicline, bupropion, NRT andunaided cessation, respectively. After 20 years,
varenicline exhibited the highest number of QALYs gained (2,144,323) against bu-
propion (1,717 QALYs); NRT (2,222 QALYs) and unaided cessation (4,191
QALYs). QALYs differences showed to be meaningful in the healthcare system.
Costs showed varenicline is the least expensive alternative with US$311,795,928
less than NRT and US$240,956,600 less than bupropion. Varenicline dominated all
smoking cessation strategies. PSA support previous findings. Acceptability curves
showed that varenicline would be cost-effective within 3 GDP per capita
threshold. CONCLUSIONS: Results suggest that varenicline would be the cost-sav-
ing treatment. In Panama, the government is responsible by law to develop smok-
ing cessation programs, thus varenicline could be helpful to enhance cost-contain-
ment policies and improve Panama health-outcomes.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) has a huge impact on
the quality of life (QOL) of patients, diminishing significantly their ability to work
and their social activity. The objective of this study was to examine if the recently
available treatment for COPD, indacaterol, improved the QOLmore cost-effectively
than the therapeutic alternatives already available.METHODS: A cost-utility anal-
ysis was performed from an institutional perspective (Mexican Institute of Social
Security, IMSS). The comparators used were salmeterol and tiotropium, both alter-
natives availablewithin theNational Formulary and recommended by theNational
Treatment Guidelines for COPD; dosage regimens compared were indacaterol 300
g vs. tiotropium 18 g, and indacaterol 150 g vs. salmeterol 50 g. QOL data was
taken from published literature; the parameter used was health-related (HR) QOL
score using St. George’s Respiratory Questionnaire (SGRQ). Resource use data was
obtained from the institution; total direct costs of physician consults, lab and im-
age tests, hospitalization and emergency room visits, and treatments were consid-
ered. The source of the unit costs was the institution, current for 2010. All costs are
expressed in local currency (Mexican Pesos, MXP). The time horizon was less than
1 year; no discount rate was used. The analytical tool used to build the model was
a decision tree. A probabilistic sensitivity analysis was performed through aMonte
Carlo simulation with 100,000 iterations to confirm the robustness of the model.
RESULTS: The results show a cost-utility ratio of $302 MXP for indacaterol, com-
pared to $317 MXP for tiotropium. Likewise, a cost-utility ratio of $298 MXP for
indacaterol was obtained, compared to $321MXP for salmeterol, corroborating that
indacaterol is a more cost-effective alternative (dominant) for the treatment of
COPD. CONCLUSIONS: From an institutional perspective in Mexico, indacaterol
improves QOL more cost-effectively (dominant) than either tiotropium or salmet-
erol for the treatment of COPD.
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RESOURCE USE AND COSTS OF EXACERBATION MANAGEMENT OF CHRONIC
OBSTRUTIVE PULMONARY DISEASE PATIENTS UNDER THE PRIVATE
HEALTHCARE SYSTEM IN BRAZIL: ROLE OF MAINTENANCE TREATMENT IN
THE EXACERBATION PREVENTION IN SEVERE PATIENTS
Nasciben V
Boehringer Ingelheim Brazil, Sao Paulo, Brazil
OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is a degenerative con-
dition with symptoms, disability and impaired quality of life that according to
PLATINO study has 15% of prevalence in the population over 40 years-old in Brazil
with airflow obstruction who previously diagnosed with chronic bronchitis or em-
physema. This study was designed to raise the resource use and economic impact
of the exacerbation from COPD under the private healthcare system and the im-
portance of maintenance treatment avoiding exacerbation.METHODS: Amodified
Delphi panel was conducted with specialist in COPD management to capture the
clinical practice and use of resources to non severe and severe exacerbation treat-
ment. Exacerbation reduction from maintenance treatment with tiotropium was
taken from literature. Only direct medical costs were taken. For physician fees,
procedure reimbursement, inpatient costs and drug costs were gathered frompub-
lic lists (CBHPM 5th, Kairos, PHROASA) that are the base for negotiations between
providers and payers. The Brazilian guideline for economic evaluation was fol-
lowed to guarantee the methodological robustness (Vianna, 2008). Discounts were
not applied for the time horizon of 1 year. RESULTS: For each non severe exacer-
bations the total cost was R$ 413 (physician fees for emergency, ambulatory care
and consults in the hospital was R$ 180, R$ 210 for drugs and R$ 23 for oxygen
therapy) and for severe cases total cost was R$ 5,221 per patient (average LOS of 11
and cost of R$ 2,228, physician fees for consults R$ 581, R$ 483 for exams and R$
2583 for drugs and R$ 228 for oxygen therapy). Considering the incorporation of
tiotropium in the maintenance phase, a reduction of up to 25% in the average
exacerbation costs compared with the usual care of R$ 1,831. CONCLUSIONS:
Tiotropium showed potential to reduce the economical burden of COPD due to
exacerbation’s reduction and delay.
Respiratory-Related Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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COPD MAINTENANCE MEDICATION ADHERENCE: INFLUENCE ON
HOSPITALIZATION AND SPENDING IN A MEDICARE POPULATION
Simoni-Wastila L1, Wei YJJ1, Qian J1, Zuckerman IH1, Stuart B1, Shaffer T1, Dalal A2,
Bryant-Comstock L2
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OBJECTIVES:This study examines the influence ofmedication-taking behaviors on
hospitalization and spending among Medicare beneficiaries with chronic obstruc-
tive pulmonary disease (COPD).METHODS: Our cohort was a random 5% national
sample of Medicare beneficiaries with COPD enrolled in stand-alone Medicare Part
D plans (PDPs) in 2006 and 2007 who used COPD maintenance medications
(n43,666). We conducted a retrospective cross-sectional analysis of the associa-
tion of COPD maintenance medication discontinuation (1/0) and adherence (Med-
ication Possession Ratio measured as low [MPR0.20], moderate [MPR 0.3-0.7] or
high [MPR0.80] on all-cause hospitalization and total, Medicare Part A, B, and D
spending. COPD diagnosis was assessed using ICD-9-CM codes (491.xx, 492.xx,
496.xx) in inpatient and outpatient administrative claims from January 1, 2006 to
June 30, 2006 (baseline). We examined outcomes for 18 months from July 1, 2006-
December 31, 2007. Maintenance medications recommended for the management
of COPD included inhaled corticosteroids (alone or in combinationwith long-acting
2–agonists), anticholinergics, and methylxanthines. Logistic regression analysis
was used to estimate any hospitalization and ordinary least squares regression to
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model spending. We report adjusted relative risks (adjusted_RR) with 95% confi-
dence intervals (CIs) formultivariable logistic regressions and adjusted coefficients
with standard errors and p values for results from OLS models, controlling for
covariates. RESULTS: Inmultivariablemodels, COPDmaintenancemedication dis-
continuation increased hospitalization risk (RR 1.08, 95%CI 1.06, 1.10), while high
MPR reduced hospitalization risk (RR  0.93, 95% CI 0.91, 0.95) compared to low
MPR. Medication discontinuation also increased total spending by $2350 (p 
0.001), driven largely by Part A spending ($4039; p 0.001) and offset by Part D drug
spending reductions (-$1,833; p 0.001). High adherence significantly reduced total
spending by $4273 (p 0.001),whilemoderate adherence reduced spending by $936
(p  0.05) relative to poor adherence. CONCLUSIONS: Findings highlight the im-
portance of adhering to prescribed pharmacologic regimens of COPDmaintenance
medication in reducing hospitalizations and associated costs.
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NON-ADHERENCE IN ISONIAZID TREATED PATIENTS AS MEASURED BY THE
TEMPTATION TO SKIP THERAPY (TEST) SCALE
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OBJECTIVES: Isoniazid ishighly effectiveandwidelyused forTBpreventionand treat-
ment; however itmust be used consistently for 6 to 9months to treat latent TB,which
is usually asymptomatic. The combination of long-term therapy and lack of symp-
toms results in high risk for non-adherence. The cost of subsequent treatment for
patients with isoniazid resistance is estimated at $1million per reactivation case pre-
vented. These data highlight the need for more information about adherence with
isoniazid in patients with latent TB. The specific aim of this study was to document
adherence patterns in patients with latent TB and examine associations with patient
characteristics. We also examined patient’s attitudes toward intentional nonadher-
ence in relation tomedical doubts, lack of social support, andmedication side effects
by using the Temptation to Skip Therapy (TEST) scale. METHODS: Questionnaires
were completed at baseline by 211 isoniazid treated patients (aged 18-66) at the Rhode
IslandTuberculosis Clinic. Adherencewas subsequentlymeasured at 6 and 9months.
The average score was computed for each TEST subscale and the association with
each subscale and the Morisky Medication Adherence Scale (MAS) was examined.
RESULTS: Adherence to INH therapy was 45% (by MAS). Latent TB patients scored
highest on theSideEffect (Mean1.62) and lowest on theTESTMedicalDoubt subscale
(Mean  1.47). Non-Whites exhibited higher mean scores on the Medical Doubt sub-
scale indicating uncertainty toward the need for therapy. Patients with higher scores
on the Medical Doubt and Side Effect subscales had higher non-adherence levels.
CONCLUSIONS: Latent TB patients exhibited low adherence with isoniazid therapy.
Fear of side effects and doubts about the need for medication were related to discon-
tinuation of therapy. Better understanding of attitudes toward isoniazid therapymay
be beneficial for improving adherence, and reducing costs associated with isoniazid
treatment.
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IMPACT OF MORBIDITY, PSYCHOLOGICAL DISTRESS AND LUNG FUNCTION ON
PHYSICAL FUNCTIONING IN A RETIRED POPULATION
Roberts M, Mapel D
LCF Research, Albuquerque, NM, USA
OBJECTIVES: Physical functioning scales have been used to assess risk for disabil-
ity, propensity for healthcare utilization, and impact on quality of life (QOL) scores.
Understanding related factors in a nationally representative older population is
important for designing effective physical functioning improvement programs,
potentially decreasing utilization and increasing QOL.METHODS: To measure im-
pact of demographics, morbidities, psychological distress and lung function on
physical functioning among the retired, a retrospective main effects analysis of
data from the Health and Retirement Study (HRS) for subjects surveyed in 2006 and
2008 was performed on a sample of 13,129 patients aged 50 years (M  66.14;
45.9% male) with lung function measurement (peak expiratory flow (PEF)), and
psychological distress (symptoms of anxiety and depression) assessment (8 ques-
tion Center for Epidemiologic Studies Depression Scale (CES-D8)), and self-reported
confirmation of morbidity diagnoses. Morbidities were diabetes (19.4%), chronic
obstructive pulmonary disease (COPD) (9.8%), heart disease (23.6%), cancer (13.7%),
and stroke (6.0%). RESULTS: In a weighted multiple regression model of physical
function difficulty score, 49% of the variance was explained by analyzed variables.
In a weighted logistic regression model for difficulties with 4 physical functions
(max12), adjusted for age and race, odds were significantly higher for subjects
reporting morbidities of frequent pain (odds ratio range (ORR) 6.0-7.7), COPD (ORR
2.4-3.4), stroke (ORR 2.0-2.8), heart disease (ORR 1.6-1.9), or diabetes (ORR 1.7-2.2). In
addition, greater risk for physical function difficulties was associated with psycho-
logical distress (ORR 2.2-3.0) and low PEF scores (80% of predicted, ORR 1.7-2.1).
Among retirees with COPD, 59.3% had low PEF scores compared to 23.7% without;
34.8% had psychological distress compared to 19.6% without. CONCLUSIONS: The
secondary database of longitudinal data from the HRS offers valuable information
for understanding factors associated with functional limitations. Mental health
and lung functioning are potential areas for focusing improvement efforts.
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FACTORS INFLUENCING SATISFACTION WITH COPD MAINTENANCE
MEDICATION: CONCEPTS ELICITED THROUGH QUALITATIVE INTERVIEWS
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BACKGROUND: Patients with COPD have demonstrated poor adherence and persis-
tence with inhaledmaintenancemedications, suggesting low satisfaction with exist-
ing therapies. An understanding of the factors driving treatment satisfaction from the
patient perspective is necessary to develop or modify therapies to address patients’
concerns. OBJECTIVES: To examine factors influencing patients’ satisfaction with
COPD maintenance medications. METHODS: Fifty-two one-on-one semi-structured
telephone interviewswere conductedwithCOPDpatients to gather informationabout
attributes that influence satisfaction with COPD maintenance medication and deliv-
ery devices. Participantswere selected from two sources: patientswho recently exited
one of two trialswith aclidiniumbromide via theGenuair™ inhaler(n32) or non-trial
patients recruited from clinics who recently received treatment with tiotropium bro-
mide via the HandiHaler™(n20). A coding scheme for categorizing responses was
developed and interview transcripts were analyzed using qualitative software.
RESULTS: Focus group participants had amean age of 66.5 years; were 51.9% female;
andhadadiagnosis ofmoderate (GOLD II) to severe (GOLD III) COPD. Four components
of patients’ satisfaction were identified: ease of use/convenience, efficacy, onset of
action, and side effects. Regarding ease of use/convenience, patients most frequently
cited the importance of device portability (31%), device simplicity (27%), and whether
the device indicated that a dose had been received (25%). For efficacy, patients most
frequently mentioned whether the product made them feel that their airways were
open and they could catch their breath (42%), that the medication kept symptoms
from worsening (33%), and that the medication improved ambulatory ability (29%).
Nearly half of patients (46%) noted onset of action as important. Finally, thirty-five
percent of patients noted that side effects affected their satisfaction with treatment.
CONCLUSIONS: Ease of use/convenience, efficacy, onset of action, and side effects
drive patients’ satisfactionwith inhaled COPDmaintenancemedications. COPDmed-
ications and delivery devices that address these factors may improve patient adher-
ence and persistence.
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SCORE TO QUANTIFY THE SEVERITY OF RESPIRATORY SYMPTOMS OF COPD
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OBJECTIVES: Although respiratory symptoms are a defining feature of COPD, a
standardized method for assessing their day-to-day severity suitable for testing
treatment effects in clinical trials has not been established. This study examined
the reliability and validity of the E-RS (EXACT-Respiratory Symptoms), a respira-
tory symptom score derived from the 11 respiratory items of the 14-item EXACT, a
daily diary assessing exacerbations of COPD. METHODS: Content validity was as-
sessed through analyses of qualitative data from 84 patients with COPD, including
secondary analyses of data collected during EXACT development (n63) and data
from four new focus groups with patients without recent history of exacerbation
(n21). Quantitative properties were tested through secondary analyses of data
from 188 stable COPD patients gathered over 7 days during the first EXACT valida-
tion study. RESULTS: Qualitative: Sample mean (SD) age65(10), 44% male, mean
FEV11.2(0.4) L. Patient descriptions of respiratory symptoms during stable disease
were consistent with the E-RS content, wording, and structure. Quantitative: Sam-
plemean (SD) age66 (10), 50%male,mean FEV11.2(0.5) L. Factor analysis showed
three subscales: RS-Breathlessness (5 items), RS-Cough & Sputum (3 items) and
RS-Chest (3 items). For RS-Total and subscale scores, respectively: Reliability, in-
ternal consistency (alpha) 0.88 0.86, 0.73, 0.80; test-retest (ICC) Day 1 to 7 (n171)
0.73; 0.71; 0.69; 0.62. Validity: Correlations (Spearman’s) with St. George Respira-
tory Questionnaire – COPD (SGRQ-C) 0.75; 0.69, 0.58, 0.52, modified Medical Re-
search Council dyspnea scale (mMRC)0.33; 0.38, 0.24, 0.16, and rescuemedication
use 0.32; 0.34, 0.26, 0.17 (p0.05 to 0.0001). CONCLUSIONS: Results suggest the
E-RS is a valid and reliablemethod for evaluating severity of respiratory symptoms
in COPD; the daily diary structure permits assessment of day-to-day variability and
severity over time. Further research is needed to evaluate performance over longer
assessment periods and in response to treatment, and to refine score interpreta-
tion.
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THE DEVELOPMENT OF A PATIENT-REPORTED OUTCOME INSTRUMENT TO
EVALUATE NIGHTTIME SYMPTOMS OF COPD
Palsgrove A1, Schaefer M1, Hareendran A2, Houghton K2, Mocarski M3, Carson R3,
Make B4
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OBJECTIVES: There is currently no validated tool to evaluate nighttime symptoms
in patients with COPD. The purpose of this study was to develop and test a patient
reported outcome (PRO) self-administered questionnaire for evaluating COPD
symptoms experienced during the night.METHODS: A review of the literature and
interviews with six clinical experts informed the development of a framework for
exploring patients’ experience with nighttime symptoms of COPD. Four focus
groups were conducted with twenty-seven subjects who experienced COPD symp-
toms at night or in the earlymorning. Trained interviewers used a semi-structured
interview guide, startingwith open ended questions. Grounded theorywas applied
using qualitative analysis software to identify key concepts and determine concept
saturation. A conceptual framework was developed to depict patients’ experience
with COPD symptoms at night. Items and response options were generated based
on the qualitative data. Subsequently, one-on-one cognitive debriefing interviews
were conducted with 10 COPD patients to assess item readability, comprehensive-
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